Tel Aviv (Sep 6, 2018) – BioLight is pleased to announce that today, its subsidiary IOptima Ltd., (“IOptima“), announced it has received approval to register a patent from the Canadian Patent Office (the “Patent“).
The Patent, owned by IOptima, is designed to protect the core technology of the IOPtiMate™ system and its activity on the eye, for the purpose of a non-invasive procedure for the treatment of
glaucoma. The expiry date of the Patent, after its registration, is December 31, 2029.
 After completing the first phase of the investment and purchase agreement with the Chinese pharmaceutical company (the “Agreement”), BioLight holds, via XL Vision Sciences Ltd., 57% of the issued and share capital of IOptima (approximately 55% in full dilution). For additional information regarding the Agreement, please see Biolight’s report of March 29, 2018.Link to Newsroom